FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315480957> ?p ?o ?g. }

• W4315480957 abstract "Interleukin (IL)-34 and IL-38 are associated with cardiovascular disease (CVD). However, their involvement in atrial fibrillation (AF) and AF-associated adverse events remains uncertain. Therefore, we aimed to investigate their association with various AF prognostic factors in a cohort study and assessed their predictive value for the prognosis of patients with AF.Patients with new-onset non-valvular AF were consecutively enrolled between 2013 and 2015 at the Department of Cardiovascular Medicine of the Southwest Hospital of the Army Medical University (Third Military Medical University) in Chongqing, China. The endpoints included stroke and all-cause mortality. The baseline levels of plasma IL-34, IL-38, NT-proBNP, high-sensitivity cardiac troponin T (hs-cTnT), and GDF-15 were measured and their correlation with AF-related adverse events were analyzed in a Cox proportional-hazards regression model. The C-statistic, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate the performance of the AF prognostic models. Decision curve analysis (DCA) was used to evaluate the clinical net benefit of the original and modified models.A total of 299 patients with new-onset AF were enrolled. During the median follow-up time of 28 (IQR: 27, 29) months, the higher levels of IL-34 were associated with a lower risk of stroke, and the higher levels of IL-38 were associated with an increased risk of all-cause death (all adjusted P < 0.05). In addition, elevated hs-cTnT and NT-proBNP concentrations were associated with a higher risk of stroke and all-cause mortality (all adjusted P < 0.05). Furthermore, the CHA2DS2-VASc score combined with IL-38 and NT-proBNP significantly improved the C-statistic, IDI, and NRI (all P < 0.01). There was no statistically significant difference (all P > 0.05) in the discrimination power between the preference models and the ABC (age, biomarkers, and clinical history) score for the two prognostic outcomes.Our results suggested that IL-34 and IL-38 were independently associated with stroke and all-cause mortality in patients with AF. Moreover, adding IL-38 and NT-proBNP to the CHA2DS2-VASc score significantly improved its predictive ability of AF-related all-cause death. Finally, the preference model performed equally well as the ABC score in predicting AF prognosis." @default.
• W4315480957 created "2023-01-11" @default.
• W4315480957 creator A5000898936 @default.
• W4315480957 creator A5029768320 @default.
• W4315480957 creator A5046709081 @default.
• W4315480957 creator A5049751624 @default.
• W4315480957 creator A5051766224 @default.
• W4315480957 creator A5065294248 @default.
• W4315480957 creator A5072242179 @default.
• W4315480957 creator A5076118607 @default.
• W4315480957 creator A5083862643 @default.
• W4315480957 date "2023-01-09" @default.
• W4315480957 modified "2023-10-12" @default.
• W4315480957 title "Prognostic value of interleukin-34 and interleukin-38 in patients with newly diagnosed atrial fibrillation" @default.
• W4315480957 cites W1971347950 @default.
• W4315480957 cites W1972837977 @default.
• W4315480957 cites W1976682338 @default.
• W4315480957 cites W1994315223 @default.
• W4315480957 cites W2012042386 @default.
• W4315480957 cites W2048000549 @default.
• W4315480957 cites W2050568107 @default.
• W4315480957 cites W2052943307 @default.
• W4315480957 cites W2062608061 @default.
• W4315480957 cites W2065036402 @default.
• W4315480957 cites W2070601915 @default.
• W4315480957 cites W2086723809 @default.
• W4315480957 cites W2093493917 @default.
• W4315480957 cites W2112316706 @default.
• W4315480957 cites W2121394112 @default.
• W4315480957 cites W2129925362 @default.
• W4315480957 cites W2133650808 @default.
• W4315480957 cites W2142737918 @default.
• W4315480957 cites W2145179900 @default.
• W4315480957 cites W2147925490 @default.
• W4315480957 cites W2151074096 @default.
• W4315480957 cites W2165037352 @default.
• W4315480957 cites W2166339706 @default.
• W4315480957 cites W2212816915 @default.
• W4315480957 cites W2516518196 @default.
• W4315480957 cites W2548096594 @default.
• W4315480957 cites W2563589092 @default.
• W4315480957 cites W2602322576 @default.
• W4315480957 cites W2749613778 @default.
• W4315480957 cites W2765549411 @default.
• W4315480957 cites W2772128948 @default.
• W4315480957 cites W2792355005 @default.
• W4315480957 cites W2809870713 @default.
• W4315480957 cites W2957544571 @default.
• W4315480957 cites W3012883283 @default.
• W4315480957 cites W3026163675 @default.
• W4315480957 cites W3082188176 @default.
• W4315480957 cites W3123126572 @default.
• W4315480957 cites W4205645630 @default.
• W4315480957 doi "https://doi.org/10.3389/fcvm.2022.1072164" @default.
• W4315480957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36698935" @default.
• W4315480957 hasPublicationYear "2023" @default.
• W4315480957 type Work @default.
• W4315480957 citedByCount "1" @default.
• W4315480957 countsByYear W43154809572023 @default.
• W4315480957 crossrefType "journal-article" @default.
• W4315480957 hasAuthorship W4315480957A5000898936 @default.
• W4315480957 hasAuthorship W4315480957A5029768320 @default.
• W4315480957 hasAuthorship W4315480957A5046709081 @default.
• W4315480957 hasAuthorship W4315480957A5049751624 @default.
• W4315480957 hasAuthorship W4315480957A5051766224 @default.
• W4315480957 hasAuthorship W4315480957A5065294248 @default.
• W4315480957 hasAuthorship W4315480957A5072242179 @default.
• W4315480957 hasAuthorship W4315480957A5076118607 @default.
• W4315480957 hasAuthorship W4315480957A5083862643 @default.
• W4315480957 hasBestOaLocation W43154809571 @default.
• W4315480957 hasConcept C126322002 @default.
• W4315480957 hasConcept C127413603 @default.
• W4315480957 hasConcept C164705383 @default.
• W4315480957 hasConcept C2779161974 @default.
• W4315480957 hasConcept C2780645631 @default.
• W4315480957 hasConcept C50382708 @default.
• W4315480957 hasConcept C71924100 @default.
• W4315480957 hasConcept C72563966 @default.
• W4315480957 hasConcept C78519656 @default.
• W4315480957 hasConceptScore W4315480957C126322002 @default.
• W4315480957 hasConceptScore W4315480957C127413603 @default.
• W4315480957 hasConceptScore W4315480957C164705383 @default.
• W4315480957 hasConceptScore W4315480957C2779161974 @default.
• W4315480957 hasConceptScore W4315480957C2780645631 @default.
• W4315480957 hasConceptScore W4315480957C50382708 @default.
• W4315480957 hasConceptScore W4315480957C71924100 @default.
• W4315480957 hasConceptScore W4315480957C72563966 @default.
• W4315480957 hasConceptScore W4315480957C78519656 @default.
• W4315480957 hasFunder F4320321001 @default.
• W4315480957 hasLocation W43154809571 @default.
• W4315480957 hasLocation W43154809572 @default.
• W4315480957 hasLocation W43154809573 @default.
• W4315480957 hasOpenAccess W4315480957 @default.
• W4315480957 hasPrimaryLocation W43154809571 @default.
• W4315480957 hasRelatedWork W1967841144 @default.
• W4315480957 hasRelatedWork W2018480046 @default.
• W4315480957 hasRelatedWork W2319489406 @default.
• W4315480957 hasRelatedWork W2412821596 @default.
• W4315480957 hasRelatedWork W2603808924 @default.
• W4315480957 hasRelatedWork W2763816051 @default.

• next